Study
|
Region
|
Study Period
|
No. of patients
|
Follow-up (months)
|
Age (years)
|
Gender (male/female)
|
Tumor histology
|
Type of PS scale
|
Survival
|
NOS
|
---|
ccRCC
|
non-ccRCC
|
Unknown
|
---|
Bamias 2010
|
UK
|
2006–2009
|
109
|
15.8 (0.1–31.5)
|
59 (30–79)
|
80/29
|
100
|
7
|
2
|
ECOG PS
|
OS
|
7
|
You 2011
|
Korea
|
2006–2009
|
78
|
10
|
59 (34–79)
|
57/21
|
78
|
–
|
–
|
KPS
|
OS, PFS
|
8
|
Steffens 2011
|
Germany
|
2005–2010
|
116
|
21 (9.5–30.3)
|
61 ± 11.1
|
79/37
|
98
|
18
|
–
|
ECOG PS
|
OS, PFS
|
7
|
Abel 2011
|
USA
|
2004–2009
|
75
|
15 (10.5–23.0)
|
60.0 (23–80)
|
54/21
|
55
|
11
|
9
|
ECOG PS
|
OS
|
8
|
Seidel 2012
|
Germany
|
2005–2011
|
119
|
NA
|
61 (27–72)
|
84/35
|
106
|
13
|
–
|
ECOG PS
|
OS
|
6
|
Powles 2014
|
UK
|
2006–2009
|
98
|
NA
|
59 (37–78)
|
75/23
|
98
|
–
|
–
|
ECOG PS
|
OS
|
8
|
Poprach 2014
|
Czech
|
2007–2012
|
319
|
15
|
62 (45–77)
|
221/98
|
309
|
NA
|
NA
|
ECOG PS
|
OS, PFS
|
7
|
Park 2014
|
Korea
|
2006–2011
|
83
|
18 (1–62)
|
57 (33–80)
|
60/23
|
83
|
–
|
–
|
KPS
|
OS, PFS
|
7
|
Kust 2014
|
Croatia
|
2008–2013
|
41
|
40 (5–48)
|
60
|
34/7
|
41
|
–
|
–
|
ECOG PS
|
OS, PFS
|
6
|
Gore 2015
|
USA
|
2005–2007
|
4543
|
13.6 (1–71.3)
|
59 (19–89)
|
3364/1179
|
4010
|
532
|
1
|
ECOG PS
|
OS
|
8
|
Shin 2015
|
Korea
|
2006–2011
|
182
|
34.6 (2.3–171.7)
|
56.9 (33–85)
|
132/50
|
182
|
–
|
–
|
KPS
|
OS, PFS
|
6
|
Wang 2016
|
China
|
2006–2015
|
282
|
37
|
58 (19–83)
|
200/82
|
233
|
49
|
–
|
KPS
|
OS
|
8
|
Rausch 2016
|
Germany
|
2003–2014
|
88
|
34.6 (26.4–42.2)
|
68.8 (30.8–81.5)
|
69/19
|
81
|
6
|
6
|
ECOG PS
|
OS
|
6
|
Chrom 2016
|
Poland
|
2010–2014
|
266
|
46.1 (41.2–51.0)
|
61 (22–85)
|
180/86
|
248
|
18
|
–
|
ECOG PS
|
OS
|
6
|
Artac 2016
|
Turkey
|
1998–2012
|
104
|
20.8 (1.8–55.5)
|
57 (29–88)
|
77/27
|
65
|
15
|
24
|
KPS
|
PFS
|
8
|
Furukawa 2016
|
Japan
|
2009–2011
|
39
|
15.1
|
61 (36–77)
|
27/12
|
39
|
–
|
–
|
KPS
|
PFS
|
7
|
Hwang 2017
|
Korea
|
2007–2013
|
56
|
20.2 (1.5–78.3)
|
60 (37–88)
|
44/12
|
51
|
5
|
–
|
KPS
|
OS
|
7
|
Teishima 2017
|
Japan
|
2007–2016
|
118
|
NA
|
64 (40–84)
|
97/21
|
102
|
16
|
–
|
ECOG PS
|
OS
|
7
|
Zucca 2018
|
Brazil
|
2008–2014
|
64
|
18.5
|
57 (30–81)
|
42/22
|
51
|
13
|
–
|
KPS
|
OS
|
7
|
- ccRCC clear cell renal cell carcinoma, PS performance status, NOS Newcastle-Ottawa score, KPS Karnofsky performance status, ECOG PS Eastern Cooperative Oncology Group performance status, NA not available